



# China BioMed Innovation & Investment Conference

International Innovative Oncology Companies Roadshow Showcase

September 22, 2019 | Suzhou, China



## CBIIC HOSTS



## INTERNATIONAL ONCOLOGY SHOWCASE ORGANIZERS





## AGENDA

**8:30 – 8:40** Welcoming remarks by **Dr. Sujuan Ba**, NFCR President and Chief Executive Officer

**8:40 – 9:00** Keynote speech by **Dr. Raju Kucherlapati**, Harvard University Paul C. Cabot Professor

### Morning Session

*Moderator: Dr. Michael Wang, NFCR Chief Strategy Officer*

Showcase Company Presentations:

**9:00 – 9:25** Dr. Adam Hill, Oncimmune, Chief Executive Officer

**9:25 – 9:50** Dr. Hal Gunn, Qu Biologics, Chief Executive Officer

**9:50 – 10:15** Dr. Michael Molyneaux, Sirnaomics, Chief Medical Officer

**10:15 – 10:40** Dr. Christian Rohlf, Oxford Biotherapeutics, Chief Executive Officer

**10:40 – 11:05** Dr. Jin-San Yoo, PharmAbcine, Chief Executive Officer

**11:05 – 11:30** Mr. Earle Holsapple, SciTech Development, President

**11:30 – 11:55** Mr. Keith Lingenfelter, OTraces, Chief Executive Officer

**11:55 – 12:20** Dr. Paul Abrams, International Cancer Impact Fund, Partner

**12:20 – 12:25** Wrap-up by Dr. Wang

*-Break for Lunch-*

**1:30 – 1:40** Reconvening remarks by **Dr. Sujuan Ba**, NFCR President and Chief Executive Officer

**1:40 – 2:00** Keynote speech by **Ms. Catherine Pan**, Dorsey & Whitney Partner

### Afternoon Session

*Moderator: Mr. Bradley Gillenwater, NFCR Senior Director for Global Program Development*

Showcase Company Presentations:

**2:00 – 2:25** Dr. Cesare Spadoni, OncoHeroes, Chief Operating Officer

**2:25 – 2:50** Mr. Peikwen Cheng, Yiviva, Chief Executive Officer

**2:50 – 3:15** Dr. Alex Meltzer, Rasio Therapeutics, Vice President of Drug Discovery

**3:15 – 3:40** Dr. Haiyong Han, Stromatis Pharma, Co-founder & Board Member

**3:40 – 4:05** Mr. Sijme Zeilemaker, Immunicum, Senior Business Development Director

**4:05 – 4:30** Dr. Jiming Zhou, 20/20 GeneSystems, VP of East Asia Business Development

**4:30 – 4:55** Dr. David Shao, Yisheng Biopharma, Chief Executive Office

**4:55 – 5:00** Wrap-up by Mr. Gillenwater

*-Conclude-*

### SPEAKERS



**Dr. Sujuan Ba**

Dr. Sujuan Ba serves as the President and CEO of the National Foundation for Cancer Research. She is also the Founder and CEO of the Asian Fund for Cancer Research. Dr. Ba co-founded and serves as a Founding Board Member of the Global Coalition for Adaptive Research (GCAR) in 2017, the organizing body leading the global implementation of GBM AGILE, a groundbreaking adaptive clinical trial initiative designed to produce new and better treatments for glioblastoma multiforme, a fatal brain cancer. Dr. Sujuan Ba also serves as the Founding President and CEO for AIM-HI Accelerator Fund, an organization focused on advancing oncology startups through venture philanthropy and impact investments, which helped launch 10 oncology start-ups.

Dr. Ba has served continuously for 14 years as co-Chair of the Prize Selection Committee of the Szent-Györgyi Prize for Progress in Cancer Research. The Committee is comprised of academic leaders and pharmaceutical industry executives, and the annual Prize has become one of the premier cancer research awards in the world. Dr. Ba also served as the President of Chinese Biopharmaceutical Association (Rockville, USA) in 2010-2011.

Since 2001 Dr. Kucherlapati is the Paul C. Cabot Professor of Genetics and Professor of Medicine at Harvard Medical School and was the first Scientific Director of the Harvard Medical School-Partners HealthCare Center for Genetics and Genomics (HPCGG). Dr. Kucherlapati contributed to several different areas of research. He was a Member and Chair of several review committees at the NIH, was a Member of the National Advisory Council for Human Genome Research at the National Human Genomics Research Institute, and was a Co-Chair of the steering committee for the National Cancer Institute’s Mouse Models for Human Cancer Consortium. He served on the editorial board of the New England Journal of Medicine and was Editor-In-Chief of the journal Genomics. He is a Fellow of the American Association for the Advancement of Science and a member of the National Academy of Medicine. Dr. Kucherlapati was a member of the Presidential Commission for the Study of Bioethical Issues during the Obama administration.



**Dr. Raju Kucherlapati**

Dr. Kucherlapati was a Founder of several biotechnology companies including Cell Genesys, Abgenix (acquired by AMGEN) and Millennium (acquired by Takeda). He serves on the boards of several privately held biotechnology companies and is a Board Member of a publicly traded company called Puretech Health. He has been active in promoting precision medicine in China and is the co-Chair of the International Cancer Precision Medicine Conference that just held its fourth annual meeting in Chongqing.



**Catherine Pan**

Ms. Pan is a Partner of Dorsey & Whitney LLP. She is a member of Dorsey's Management Committee, the Corporate Group Head of the firm's New York offices; she also leads the firm's globally recognized U.S.-China transactional practice. Ms. Pan is a highly successful cross-border and international business lawyer with a strategic approach to the business of law. She leads strategic corporate transactions that include mergers, acquisitions, joint ventures, equity and debt financings, and other cross-border corporate transactions. In addition to her transactional experience, Ms. Pan also oversees risk management, dispute resolution and investigation matters for corporate clients and their officers and directors. She has a strong client following among some of the world's largest corporations, investment funds, financial institutions and business leaders. She frequently serves as their chief outside legal counsel.

Ms. Pan focuses on life science, healthcare, food, technology, financial services, and certain other regulated industries. A graduate from Harvard Law School with full scholarship, Ms. Pan also holds law degrees from China and Sweden. She has been awarded the honors of "Super Lawyer Rising Star" and has been selected by the New York Times as a "Top Woman Attorney" in New York. She serves in various leadership positions at the firm and is fluent in Chinese and English.

## PRESENTERS



**Dr. Adam Hill**  
Oncimmune  
Chief Executive Officer



**Dr. Hal Gunn**  
Qu Biologics  
Chief Executive Officer



**Dr. Michael Molyneux**  
Sirnaomics  
Chief Medical Officer



**Dr. Jin-San Yoo**  
PharmAbcine  
Chief Executive Officer



**Mr. Earle Holsapple**  
SciTech Development  
President



**Mr. Keith Lingenfelter**  
OTraces  
Chief Executive Officer



**Dr. Paul Abrams**  
International Cancer Impact Fund  
Partner

## PRESENTERS



**Dr. Cesare Spadoni**  
OncoHeroes  
Chief Operating Officer



**Mr. Peikwen Cheng**  
Yiviva  
Chief Executive Officer



**Dr. Alex Meltzer**  
Rasio Therapeutics  
Vice President of Drug Discovery



**Dr. Haiyong Han**  
Stromatis Pharma  
Co-Founder & Board Member




**Dr. Jiming Zhou**  
20/20 GeneSystems  
VP of East Asia Business  
Development



**Dr. David Shao**  
Yisheng Biopharma  
Chief Executive Officer

## COMPANY DESCRIPTIONS

**Oncimmune Plc**, a UK publicly traded company (LSE: ONC) with R&D facilities in the UK, USA, Germany, and China, is a leader in the development of immunodiagnostics in multiple cancer indications to support clinical decisions across the care pathway. Over the last two decades, Oncimmune has been working to revolutionise both detection of cancer, and its treatment by harnessing the power of the most sophisticated disease detection system known, the human immune system, able to detect cancer in its early stages. Our range of diagnostic tests enables clinicians to detect cancer on average four years before standard diagnosis, while our technology platform and sample biobanks are helping healthcare companies to develop new cancer treatments. Most recently, we have announced the positive top line readout of ECLS, the largest randomised study of a blood-measured biomarker for lung cancer detection in a screening population and signed strategic partnerships to deploy this blood test in the US, Russia, and China.



**Qu Biologics**, a clinical stage biotech company, has developed a patented immuno-oncology platform, Site Specific Immunomodulators (SSIs), that recruit activated anti-cancer immune cells into targeted tumors to transform the way cancer is treated. SSIs work as stand-alone therapies and substantially enhance the efficacy of a broad range of other cancer treatments, including CAR-T cell therapy chemotherapy, cancer vaccines, and sting agonist. Qu Biologics has completed three Phase 2 studies and treated more than 360 patients with SSIs, with a very good safety profile and compelling clinical data. SSIs activate multiple important anti-cancer pathways simultaneously, including NK cell and M1 macrophage recruitment and activation, down-regulation of PD-1 and up-regulation of the NKG2D pathway. These parallel multiple important mechanisms relieve immune suppression in the tumor microenvironment and increase tumor immunogenicity. SSIs have transformative potential in CAR-T cell therapy in solid tumors by shifting the tumor microenvironment from 'cold' to 'hot', and markedly increasing CAR-T cell infiltration and efficacy in solid tumors. Qu Biologics is seeking USD \$35M pre-IPO equity funding and additional collaborations/partnerships with leading CAR-T cells companies.



**Sirnaomics** is a clinical stage biopharmaceutical company leveraging an outstanding level of knowledge and experience in RNA interference (RNAi) technology to forge a path to high value creation through discovery and development of therapeutics for human disorders with unmet medical needs. The key differentiating feature is the proprietary Polypeptide Nano-Particle (PNP) technology for small interfering RNA (siRNA) drug delivery. This technology allows accessing the tumor micro-environment (TME), as well as various cell types in the liver. Through internal research and collaborations with prominent labs at the National Institutes of Health, Johns Hopkins, Duke, Penn State and the University of Maryland, Sirnaomics has developed a strong portfolio of intellectual property covering RNAi therapeutic products, key biological mechanisms of action and a unique PNP delivery system. The management team, led by Patrick Lu, Ph.D., collectively has extensive drug development experience, as well as specialized expertise in the areas of oligonucleotide therapeutics and nanoparticle-mediated delivery. It has raised over \$70 million for the development of a novel siRNA therapeutic candidate, STP705, for the treatment of cancer and fibrosis diseases.



## COMPANY DESCRIPTIONS



**Oxford Biotherapeutics (OBT)** is a clinical stage oncology company with a pipeline of immune-oncology and antibody-drug conjugate based therapies. Our commitment to the advancement of the field of cancer immunotherapy is focused on (i) the identification of novel immune check point targets, (ii) the optimization of multiple antibody and bi-specific technologies for immuno-oncology and (iii) a broad clinical alliance for rapid testing in numerous cancer types. The product pipeline of OBT currently consists of (i) T-cell based therapies, namely check point modulators, (ii) NK cell based therapies, namely antibody dependent cell mediated toxicity, and (iii) antibody drug conjugates. Our aim is to re-engage and recruit the body's immune system to attack cancer cells, providing a targeted treatment strategy to patients most in need. This has been enabled by the expertise of a team of specialists in immuno-oncology and immuno-therapeutics. Together, we have established a unique insight into the cancer-immune cell synapse by building one of the world's largest integrated oncology immune cell surface protein libraries. Our current pipeline consists of no fewer than five candidates developed internally.




**PharmAbcine** is a clinical stage biopharma, publicly trading at KOSDAQ (208340). We generate fully human antibodies by using HuPhage Display Library and a unique antigen customized selection system. We also have multiple technology platforms including a patients derived cancer stem cell library, proprietary animal model systems, bispecific and multi-specific antibody platforms such as DIG-Body, PIG-Body and TIG-Body, and the 3G Expression, a high performing cell line generation platform. We successfully isolated olinvacimab (previously known as TTAC-0001 or tanibirumab), a fully human anti-VEGFR2 (KDR) neutralizing IgG that recognizes a unique epitope and has cross-species reactivity. Olinbvacimab has distinct property compared to ramucirumab (Cyramza) and the safety and efficacy were further tested in terminal stage GBM patients. GBM is a stage 4 and the most aggressive type of glioma with 14M life expectancy. We are also developing PMC-309 anti-VISTA antibody as well as multiple bi-specific antibodies including PMC-001 & PMC-002R neutralizing VEGFR2 and TIE2 pathways, PMC-201 blocking VEGFR2 and DLL4 pathways, and PMC-122 blocking PDL1 and CD47. We believe that we are in a good position to succeed to bring new drugs to market and are looking for opportunities in licensing out our assets, co-development, and/or strategic investment.




**SciTech Development LLC** is a clinical stage biopharmaceutical company with strong clinical KOL backing that reformulated the safe & efficacious anticancer agent fenretinide into an intravenous drug yielding mandated bioavailability resulting in immune-oncology and chemotherapeutic effects that produce apoptosis (programmed cell death). SciTech will be introducing its patented lead drug compound ST-001 nanoFenretinide. This novel, nanoparticle formulation targets a broad range of cancers from lymphomas and lung cancer to prostate, pancreatic, breast, colon and others where historic data suggests they are likely to respond to fenretinide. Fenretinide has been proven to be safe in prior clinical trials involving >3k patients. SciTech is seeking funding and strategic partnerships to conduct Phase 1 A & B clinical trials to reconfirm the safety and efficacy of fenretinide in its new nanoFenretinide formulation while confirming the newly identified immune MOA as a further goal of the protocol; and, also demonstrating partial efficacy in the treatment of at least 2 cancer indications. Interested parties are encouraged to go to SciTech's web page ([www.scitechdevelopment.com](http://www.scitechdevelopment.com)) to explore in detail the merits of the investment and/or collaboration opportunity.

## COMPANY DESCRIPTIONS



**OTRaces** has developed and is commercializing the only serum-based test technology capable of tracking cytokine signatures in the tumor microenvironment (TME). Our technology could be profoundly important because the cancer diagnostic content of the TME far surpasses ctDNA liquid biopsy, and it is a dynamic venue that enables real-time tracking of tumor progression and immune status. Developed in conjunction with researchers at Johns Hopkins Medicine, this approach is ideal for multi-cancer screening in that it has superior accuracy over current approaches, its software is compatible with ordinary instrumentation used in labs throughout the world and the estimated manufacturing cost is under \$2 per test. Across at least six tumor types (breast, prostate, lung, pancreatic, skin and ovarian) and over 3,000 samples, sensitivity and specificity has met or exceeded 90%. OTraces seeks a \$5 million investment that could include a collaboration with an established company in China to co-develop this technology, and we are prepared to establish a subsidiary in the country. Furthermore, we are preparing to pursue Asian clinical validation of our platform upon access to serum samples.



The lecture will highlight US, European, and Global venture activity and performance over the past decade and year in life science venture capital, with a focus on oncology venture capital. The talk will focus on venture capital inflows, outflows, and distribution activity, life science venture capital performance from a return, loss ratio, and holding period standpoint, oncology venture capital performance from a return, loss ratio, and holding period standpoint, and an overview of recent developments in the oncology market and marquee transactions.



**Oncoheroes** is a ground-breaking biotech company focused on the discovery, development and commercialization of better drugs for children and adolescents with cancer. The company is headquartered in Boston, US, with a discovery lab in Barcelona, Europe. Oncoheroes was co-funded by Ricardo Garcia (serial entrepreneur), Cesare Spadoni (drug development professional), Marc Goldberg (savvy Life Science VC investor) and Marco Muñoz (seasoned fundraiser). The management team is formed by drug development and industry professionals in US and Europe and the company. Oncoheroes will generate new proprietary assets through strategic collaborations with innovative technology companies. A pre-clinical drug candidate is expected to be delivered by the end of 2020 for the treatment of medulloblastoma. Oncoheroes is also actively looking for in-licensing clinic-ready opportunities in the pediatric cancer space. The company's first asset is volasertib, a PLK1 inhibitor that was in-licensed from Boehringer Ingelheim. Volasertib comes with preclinical and early clinical data in support of further development for rhabdomyosarcoma. Clinical activities are expected to begin in 2020. The company has also access to data supporting biomarker-based approaches for a number of selected adult cancer indications. Oncoheroes is open to discuss sub-licensing deals for volasertib.



## COMPANY DESCRIPTIONS



**Yiviva** is a clinical-stage biotech, co-founded by Yale University and Professor Yung-Chi Cheng, developing first-in-class, multi-target therapeutics to prevent, treat and cure complex, heterogeneous aging-associated diseases - with a focus on cancer and inflammatory diseases. Yiviva's lead candidate cancer drug YIV-906 is a platform botanical drug that can increase efficacy, safety and response rate for Immunotherapy (PD-1, PD-L1, CTLA4), Chemotherapy, and Radiation therapy. In Phase I/II clinical studies (liver, colorectal, pancreatic, rectal cancer) in almost 200 patients, promising data suggests YIV-906 can benefit cancer patients by 1) Increasing Survival - by activating the innate immune system (via polarization of M1 macrophages), 2) improving Quality Life - by reducing inflammation and side effects (via 4 inflammation pathways NFkB, COX2, iNOS, IL-6) 3) Speeding up Tissue Recovery (by promoting progenitor and stem cell growth via WNT pathway). The US FDA has granted YIV-906 two orphan drug designations for liver and pancreatic cancers. This year Yiviva will begin enrolling patients in an international Phase II liver cancer study in the US, China, Taiwan and Hong Kong with the potential to be first line therapy. Yiviva looks forward to meeting with investors (Series B) and strategic partners (co-development and licensing).



**Rasio Therapeutics**, based in Baltimore, MD, is a preclinical stage drug development company focusing on designing and developing small molecules for cancer treatment. Rasio's most developed program consists of a cluster of artemisinin derivatives, with lead candidate ART631, that show strong efficacy in preclinical in vivo models of AML with strong PK/PD. Artemisinins as a class of drugs have historically been used in the treatment of malaria and demonstrate high tolerability and efficacy in patients. Rasio also leverages its computer aided drug design software, SILCS, to design both first-in-class and best-in-class small molecules for emerging cancer targets. As a spin-off of SILCSBio, the developer of the SILCS drug design platform, Rasio is able to capitalize on exclusive access to the most advanced modeling and design capabilities of the platform. With a lean, platform-driven, virtual model, Rasio Therapeutics is currently managing several drug development programs in parallel.



**Stromatis Pharma** is a privately held biotech company with research facilities in Northern Virginia, USA. Stromatis' dedicated and experienced management team is committed to commercializing therapeutics that target novel and unique targets for the treatment of cancer and fibrotic diseases. CT109 is a humanized monoclonal antibody that targets a novel immune checkpoint protein, CEACAM6, which is overexpressed in multiple cancer types. Similar to the well-known cancer immunotherapy targets PD1 and PD-L1, CEACAM6 blocks a patient's immune system from recognizing and destroying tumor cells. CEACAM6 Inhibitors can therefore revoke a patient's immune system to attack the tumor and eradicate the disease. CEACAM6 works in parallel to PD1/PD-L1, hence drugs targeting CEACAM6 could work in patients who do not respond (or respond poorly) to PD1-PD-L1 targeted drugs. CT109 has demonstrated potent anti-tumor activity in cell based assays and in animal models. Stromatis is seeking funding (equity or joint venture) for the manufacturing and IND-enabling studies of CT109.

## COMPANY DESCRIPTIONS



**Immunicum** (Nasdaq Stockholm) is a clinical-stage Swedish biotech developing allogeneic, off-the-shelf cell-based immunotherapies for solid tumors. Its lead product ilixadencel consists of inflammatory dendritic cells that are injected into the patient's tumor, recruiting and activating the patient's own immune cells to induce a tumor-specific CD8+ killer T cell response. It is a complete and safe immune primer to work in synergy with checkpoint inhibitors and systemic therapies such as kinase inhibitors. Immunicum has completed 4 clinical studies in RCC, HCC and GIST, of which it announced top-line results of its Phase II controlled study in RCC in September 2019. Ilixadencel is currently being tested in a Phase Ib/II study in combination with checkpoint inhibitors in NSCLC, HNSCC and gastric cancer, for which it entered into a collaboration with Pfizer and Merck KGaA for supply of avelumab for the Phase II part of the study. Due to the high incidence in China of the type of tumors we are currently studying, and the high level of research in immunotherapies in China, we are exploring the establishment of local key partnerships.

The early detection of cancer saves lives. According to American Cancer Society, the 5-year survival rate for Stage I Non-small cell lung cancer is 92% vs. Stage IV of 1%. Tens of millions of people are periodically screening multiple tumor biomarker panels using the blood routinely drawn at/or prior to an annual visit in China and other Eastern Asia areas. However, present approach for the screening tests is to simply adopt test kit manufacturer's cut-off value, results in low sensitivities and some cancers being missed. **20/20 GeneSystems, INC** has been developing early cancer detection technologies for 15 years and has received multiple NIH grants over \$7 million. In collaboration with the Taiwan Chang Gung Memorial Hospital, we developed OneTest, the world's first A.I. powered (machine learning algorithms) multi-cancer early screening platform, through a 12-year large clinical studies involving more than forty thousand asymptomatic individuals. OneTest significantly improves screening sensitivities of present single threshold by 200% to 500%, and is the only platform capable of screening all 6 cancers selected by China National Cancer Center for early detection. 20/20 is seeking investment and strategic partners to enter commercial operations in China.



TLR is an important family of receptors to initiate innate immune responses upon exposure to conserved microbial components such as lipopolysaccharide (LPS) and RNA. Over the last ten years **Yisheng Biopharma** has been focusing on the development of PIKA technology, a key component in activating the immune system with great potential in designing new generation of therapeutic vaccines and immune-oncology therapeutics. Yisheng has established a series product portfolio including 3 products at clinical development stage. This presentation focuses on recent research progress in TLR agonist related products targeting various cancer indications.

## AIM-HI Accelerator Fund Startup Companies



Advancing therapeutics that target stromal stellate cells for the treatment of cancer and fibrotic diseases.



Applying small-molecule derivatives of artemisinins to treat leukemia and drug screening platform.



Developing Cancer Terminator Viruses for the targeted therapy of a diverse array of aggressive tumor types.



Exploring small-molecule inhibitors of a specific cancer-promoting protein, MDA-9 PDZ.



Discovering novel biomarkers to repurpose and develop new drugs for pediatric cancer.



Developing unique nano-delivery systems (SciTech Delivery Vehicle-SDV) to enable intravenous (IV) delivery of water-insoluble drugs.



Developing therapeutics to address aging-associated diseases with a focus on oncology and gastroenterology.



Validating potential inhibitors of a protein, STAT-3, known to be associated with multiple cancers.



Using molecular imaging to guide surgeons in performing a complete resection of tumor tissues during the first operation of Breast Conservation Surgery.



Converting oncology laboratory achievements into commercial products with market demands and regulatory approvals.

## LAST YEAR'S PRESENTERS



# China BioMed Innovation & Investment Conference

International Innovative Oncology Companies Roadshow Showcase  
September 22, 2019 | Suzhou, China



**Thank you for attending the  
2019 International Innovative  
Oncology Companies Roadshow  
Showcase**

